A review paper just published in Blood on the role of HSCT in indolent lymphma was presented

Overview of cellular therapies, regulatory aspects

Pathophysiology and Clinical management of post-transplant TMA

Presentations in transplantation in Lymphoma patients. Which patient to transplant? When? How?

Blood 2015; 126: 415-422 This paper demonstrates that in CB tranplantation for highhj risk AML the addtion of HD ARA-C before TBI/CY myeloabaltive conditioning reduces risk of relapse without added effect on TRM.

Στο πλαίσιο  ενημέρωσης του προσωπικού της ΜΜΜΟ, στις 23/5/16 και ώρα 2:00μ.μ θα γίνει μάθημα με θέμα : "Προφύλαξη λοιμώξεων στη ΜΜΜΟ".  Το μάθημα απευθύνεται στους γιατρούς, νοσηλευτές, προσωπικό ΜΜΜΟ. Εισηγητής θα είναι ο Καθ. Παθολογίας - Λοιμωδών Νοσημάτων, κ. Μ. Μαραγκός Τόπος διεξαγωγής : Μονάδα Μεταμόσχευση...

In continue to the previous educational  regarding donor search algorith (Week 10), we discussed a very nice presentation from EBMT from Katharian Fleischhauer. The data resented reflect our own experiecnce and results in which we show a reduced OS (mainly to TRM) in the...

Questions to be answered: Do we need IFI prophylaxis in HSCT recipients? Which? How long?

We discussed new data on GvHD pathophysiology, prophylaxius and treatment

 We discussed some HLA basics, the processs for finding a donor in the BMDW and how we choose the best donors. The significance of mismatchew and the option of using an haploidentical donor was extensively discussed. Twio presentations have been uploaded.

Ms Nika Konstantina, Lecturer in Biochemistry of the U of Patras explained us the signalling of the TCR. Our team is collaborating with her in a funded reasearch program aiming to prevent T cell activation via inhibition of LcK. The attached image explaines the TCR...

A very important randomized study published in NEJM. The study shows that giving ATG in sibling tranplantation reduces the risk of chronic GvHD and improves immunsuppression free OS. It must be mentioned that in Patraswe give T-cell deplertion with low dose Campath and post Tx CsA...

A patietnt  with Burkitt Lymphoma at CR1 was admitted to our unit for autologous transplantation. Should this patient be offered this consolidation treatment? Two review papers were discussed by Dr. Liga.